Q2 Earnings Estimate for CLDX Issued By Lifesci Capital

Celldex Therapeutics, Inc. (NASDAQ:CLDX) – Research analysts at Lifesci Capital issued their Q2 2025 earnings per share estimates for shares of Celldex Therapeutics in a report issued on Friday, June 13th. Lifesci Capital analyst S. Slutsky forecasts that the biopharmaceutical company will post earnings per share of ($0.85) for the quarter. The consensus estimate for Celldex Therapeutics’ current full-year earnings is ($2.48) per share. Lifesci Capital also issued estimates for Celldex Therapeutics’ Q3 2025 earnings at ($0.88) EPS and Q4 2025 earnings at ($0.90) EPS.

Several other research analysts also recently weighed in on CLDX. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Celldex Therapeutics in a research note on Friday. UBS Group cut their price target on Celldex Therapeutics from $44.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, May 9th. Canaccord Genuity Group began coverage on Celldex Therapeutics in a research note on Monday, April 28th. They set a “buy” rating and a $64.00 price target for the company. The Goldman Sachs Group cut their target price on Celldex Therapeutics from $36.00 to $31.00 and set a “neutral” rating for the company in a research note on Friday, May 9th. Finally, Morgan Stanley cut their target price on Celldex Therapeutics from $46.00 to $43.00 and set an “overweight” rating for the company in a research note on Friday, May 9th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $50.90.

Celldex Therapeutics Stock Performance

CLDX stock opened at $21.26 on Monday. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of -8.27 and a beta of 1.33. Celldex Therapeutics has a fifty-two week low of $14.40 and a fifty-two week high of $47.00. The stock has a fifty day moving average of $19.43 and a 200-day moving average of $21.71.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.06). The firm had revenue of $0.70 million for the quarter, compared to the consensus estimate of $1.08 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%.

Institutional Trading of Celldex Therapeutics

Large investors have recently modified their holdings of the business. EverSource Wealth Advisors LLC boosted its position in shares of Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 878 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of Celldex Therapeutics by 6,665.9% during the 1st quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 2,933 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of Celldex Therapeutics during the 4th quarter valued at about $81,000. AlphaQuest LLC boosted its position in shares of Celldex Therapeutics by 171.0% during the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock valued at $108,000 after acquiring an additional 2,705 shares during the last quarter. Finally, Aquatic Capital Management LLC bought a new stake in shares of Celldex Therapeutics during the 4th quarter valued at about $121,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.